AZN Stock Recent News
AZN LATEST HEADLINES
China has approved the use of AstraZeneca's blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the company said on Wednesday.
AstraZeneca is becoming a leader in the cancer therapeutics market, which is reflected in the growth of its share price. On June 25, 2024, Tagrisso, in combination with chemotherapy, was approved in Japan as the first-line treatment for people with NSCLC whose tumors have certain mutations. Tagrisso sales were about $1.6 billion in the first three months of 2024, up 12% year-over-year.
AstraZeneca PLC (LSE:AZN) has put out mixed data for the Phase III trials of its immuno-oncology (IO) drug Imfinzi, notes broker ShoreCap. There was a positive result from the Phase III NIAGARA trial looking at its use perioperatively (either side of surgery) for the treatment of bladder cancer (MIBC).
BenevolentAI (OTC:BAIVF) said that AstraZeneca PLC (LSE:AZN) has identified a target for systemic lupus erythematosus (SLE) using the former's artificial intelligence-driven drug discovery platform - the second asset selected as part of a collocation the pair have. Benevolent's tie-up with AZ began in 2019, focusing on idiopathic pulmonary fibrosis and chronic kidney disease.
AstraZeneca said on Tuesday its blockbuster cancer drug, Imfinzi, failed to improve disease-free survival in a late-stage trial to treat a type of early-stage lung cancer.
There are multiple reasons to consider exposure to pharmaceutical stocks for the long-term portfolio. First, pharma stocks have a low-beta and provide and help in reducing the overall beta of a portfolio that's overweight growth stocks.
AstraZeneca should have lots of growth ahead. Bristol Myers Squibb has what it takes to navigate a major patent cliff.
The European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for ER-positive, HER2-negative advanced or metastatic breast cancer.
AstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer fails to meet the dual primary endpoints.
AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of patients with a type of breast cancer.